The modern measles vaccination started in 1963, when the United States licensed the first live attenuated measles vaccine (Edmonston B strain) on March 21, 1963. An inactivated ("killed") vaccine was licensed the same year, but it was withdrawn by 1967 because it caused atypical measles in some recipients. Global use of measles vaccine expanded through the 1960s and 1970s, and the two-dose schedule that eliminated endemic US transmission by 2000 took shape between 1989 and 1994. Earlier experimental work dated to 1954, but 1963 marks the practical start of routine measles immunization.
The mechanism: how a weakened virus trains immunity
Measles vaccine works by mimicking infection without causing disease. The virus is attenuated, meaning it has been cultivated under laboratory conditions until it lost the ability to produce illness in healthy people while retaining the surface proteins the immune system recognizes. When injected, it replicates briefly in the body, prompting the immune system to build neutralizing antibodies and memory cells against measles.
The key target is the measles hemagglutinin protein, the viral attachment factor that lets measles bind to host cell receptors. Antibodies against hemagglutinin block that binding. Because the vaccine virus replicates, one or two doses can produce durable immunity rather than the short-lived protection seen with inactivated vaccines.
That distinction explains why the killed vaccine failed. Without replication inside cells, it generated antibodies that did not mature properly. Some vaccinated children later exposed to wild measles developed atypical measles, a severe illness with high fever and unusual rash. The episode is a classic lesson: a vaccine must trigger the right kind of immune response, not merely any antibody response.
The live vaccine's attenuation was the technical breakthrough. Growing virus in chick embryo tissue culture over many passages selected variants that replicated enough to immunize but not enough to sicken. One plain-language way to say it: the vaccine is a weakened version of the virus that teaches the body what the real one looks like.
The timeline: from laboratory to routine use
| Year | Milestone |
|---|---|
| 1954 | Enders and Peebles isolate measles virus in tissue culture |
| 1958-1960 | Live attenuated vaccine candidates tested in small trials |
| 1963 | First live attenuated measles vaccine licensed in the US (March 21) |
| 1963-1967 | Inactivated vaccine used, then withdrawn for atypical measles |
| 1968 | Improved further-attenuated vaccine (Moraten) licensed |
| 1971 | Measles, mumps, rubella combined (MMR) licensed in the US |
| 1989 | Two-dose MMR recommendation adopted after measles resurgences |
| 2000 | Endemic measles transmission declared eliminated in the US |
The dates matter because "when did measles vaccination start" has three defensible answers depending on what you mean. Experimental vaccination with candidate strains began in the late 1950s. Licensed routine vaccination began in 1963. The two-dose regimen that defines modern practice began in 1989. Confusing these is one of the most common errors in short explainers.
The 1968 Moraten strain replaced Edmonston B because it caused fewer fevers and rashes. By the 1970s, MMR had consolidated measles, mumps, and rubella into a single shot, simplifying childhood schedules. This consolidation is why many people remember "the measles shot" as part of a combination vaccine rather than a standalone injection.
Quantified context: what changed after 1963
Before vaccination, measles was essentially universal. In the United States, an estimated 3 to 4 million people were infected each year, with roughly 500 deaths, 48,000 hospitalizations, and 1,000 cases of encephalitis annually in the pre-vaccine era. Those figures are the benchmark against which vaccine impact is measured.
After routine vaccination, reported US cases fell by more than 99 percent, from hundreds of thousands of reported cases in the early 1960s to a few dozen to a few hundred in typical recent years. The CDC declared endemic transmission eliminated in 2000, meaning sustained chains of transmission no longer originated domestically. Imported cases and limited outbreaks still occur, especially in under-vaccinated clusters.
Globally, measles remains a major cause of child mortality despite vaccination. WHO estimates that measles vaccination prevented tens of millions of deaths between 2000 and 2020, though the exact figure is modeled rather than counted case by case. Measles vaccine coverage globally has hovered around 80 to 85 percent for the first dose in recent years, short of the roughly 95 percent two-dose coverage needed to interrupt transmission.
A counterintuitive detail: measles is so transmissible that a single infected person can infect 12 to 18 susceptible people in a fully vulnerable population. That basic reproduction number, among the highest of any known virus, is why outbreak control requires coverage near 95 percent rather than the lower thresholds that suffice for many other diseases.
Edge cases: who does not follow the standard path
Several groups need different handling, and this is where generic explainers usually fall short.
Infants under 12 months: maternal antibodies can interfere with vaccine response, so the first dose is usually scheduled at 12 to 15 months; earlier doses are given before international travel. Immunocompromised people: live vaccine is generally contraindicated in severe immunosuppression, so protection depends on community immunity. Pregnant women: live measles vaccine is not recommended during pregnancy. People with severe allergy to vaccine components: alternative assessment is required before vaccination. Adults without documented immunity: vaccination may still be appropriate depending on age and evidence of prior infection.
Red flags that warrant prompt medical contact after vaccination include high fever lasting more than a few days, difficulty breathing, swelling of the face or throat, or a widespread rash with severe symptoms. These are uncommon but require evaluation rather than watchful waiting.
The professional caveat here is that "contraindication" and "precaution" are not interchangeable. A true contraindication means do not give the vaccine. A precaution means weigh risks and benefits, often with expert input. Short articles routinely blur the two, which can push readers toward the wrong conclusion about their own eligibility.
Misconceptions: what the history does and does not show
The most persistent misconception is that measles vaccination arrived fully formed in 1963. In reality, it was iterative: an early killed vaccine failed, a reactogenic live vaccine was replaced, and the two-dose schedule emerged 26 years later. The start date is real, but the product and schedule have changed substantially since.
Another misconception is that the vaccine causes measles. The attenuated virus can produce a mild fever and rash in a minority of recipients, typically 5 to 12 days after vaccination. That is a vaccine reaction, not natural measles, and it does not transmit to others.
A third misconception conflates elimination with eradication. The US eliminated endemic transmission in 2000, but measles has not been eradicated globally. Outbreaks still occur where coverage gaps exist, and imported cases can seed clusters. This is why the distinction between "eliminated" and "eradicated" appears in public health reporting.
The MMR-autism claim, published in 1998 and later retracted, is not supported by large epidemiological studies and has been rejected by major health bodies. It belongs to the history of misinformation, not the history of the vaccine's development.
Normal measles immunity after two doses is high, generally in the range of 97 percent or better, though exact figures vary by study and population. One plain-language summary: two doses protect almost everyone, but no vaccine protects absolutely everyone, which is why herd coverage matters.
Practical actions: how to check and act on your own status
For most readers, the practical question is not historical but personal: am I protected? The steps below translate the history into concrete action without prescribing individual treatment.
Locate your vaccination records. Two documented MMR doses, or laboratory evidence of immunity, generally satisfy routine adult requirements. If records are missing, ask your clinician whether serologic testing or revaccination is more appropriate for your situation. Before international travel, confirm measles immunity well ahead of departure; some guidance recommends an earlier dose for infants traveling abroad. If you are immunocompromised or pregnant, discuss live vaccine contraindications with a clinician before any dose. During an outbreak, follow local health department guidance, which may specify an additional dose for certain age groups.
The action thresholds are not one-size-fits-all. Routine two-dose coverage targets roughly 95 percent at the population level to prevent sustained transmission. Individual recommendations depend on age, immune status, pregnancy, and travel, and those categories do not map neatly onto a single number. Reconcile them with a clinician rather than a web page.
One unit note: coverage percentages here refer to the proportion of a population with documented doses, not the probability an individual is protected. Those are different quantities, and mixing them leads to misleading conclusions.
Limitations: what the record cannot settle
Historical case counts before 1963 are estimates, not censuses. Reporting was incomplete, and many mild cases went uncounted, so pre-vaccine burden figures are modeled ranges rather than exact tallies. Treat them as order-of-magnitude benchmarks.
Global mortality averted by vaccination is also modeled. WHO and partners combine coverage estimates, disease surveillance, and assumptions about vaccine effectiveness to produce those numbers. The direction of the effect is robust; the precise total is not a measured count.
Finally, this article describes stable mechanisms and well-documented milestones. It does not assess any individual's immunity, and it does not recommend a specific vaccine product or schedule for a particular person.
This article is general educational information about vaccine history and immunology, not a diagnosis, treatment plan, or medical advice. It does not promise any health outcome. For questions about your own vaccination status, eligibility, or a possible reaction, consult a qualified local clinician; for severe symptoms, seek urgent care.